Purpose

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies: - Not a woman of childbearing potential (WOCBP) OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration. - Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration. - Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration. - A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration. - A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration. - Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration. - Subject agrees not to participate in other interventional studies while receiving study drug in present study. - Subject has histologically or cytologically confirmed adenocarcinoma of pancreas. - Subjects must have metastatic pancreatic adenocarcinoma that has not been previously treated with chemotherapy. - Prior treatment with fluorouracil (5-FU) or GEM administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed - If a subject received therapy in the adjuvant setting, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of adjuvant therapy. - Subject has a measurable lesion(s) on at least 1 metastatic site based on RECIST 1.1 within 28 days prior to randomization. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. - Subject's tumor sample has CLDN18.2 expression in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing - Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Subject has predicted life expectancy ≥ 12 weeks. - Subject must meet all of the following criteria based on the laboratory tests that will be collected within 14 days prior to randomization. In case of multiple laboratory data within this period, the most recent data should be used. - Hemoglobin ≥ 9 g/dl (no transfusion within 14 days of start of study treatment) - Absolute neutrophil count ≥ 1.5 x 10^9/L - Platelets ≥ 100 x 10^9/L - Albumin ≥ 2.5 g/dL - Total bilirubin ≤ 1.5 x upper limit of normal (ULN) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (≤ 5 x ULN if liver metastases are present) - Estimated creatinine clearance ≥ 30 mL/min - Prothrombin time/international normalized ratio (INR) and partial thromboplastin time ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion Criteria

  • Subject has received other investigational treatment within 28 days prior to randomization. - Subject has received radiotherapy for metastatic pancreatic adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity. - Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed. - Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies. - Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment. - Subject has a known history of a positive test for human immunodeficiency virus infection or known active hepatitis B (positive HBs antigen [Ag]) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements. 1. For subjects who are negative for HBs Ag, but hepatitis B core antibody positive, a hepatitis B virus DNA test will be performed and if positive, the subject will be excluded. 2. Subjects with positive hepatitis C serology but negative hepatitis C virus RNA test results are eligible. 3. Subjects treated for hepatitis C with undetectable viral load results are eligible. - Subject has a history of interstitial pneumonia or pulmonary fibrosis. - Subject has pleural effusion or ascites ≥ Grade 3. - Subject has an active autoimmune disease that has required systemic treatment in the past 3 months prior to randomization. - Subject has active infection requiring systemic therapy that has not completely resolved per investigator judgment within 7 days prior to randomization. - Subject has significant cardiovascular disease, including: - Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization; - History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes); - QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects; - Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for > 1 month prior to randomization.) - Subject has a history of central nervous system metastases and/or carcinomatous meningitis from pancreatic adenocarcinoma. - Subject has known peripheral sensory neuropathy ≥ Grade 2 unless the absence of deep tendon reflexes is the sole neurological abnormality. - Subject has had a major surgical procedure ≤ 28 days prior to randomization. - Subject without complete recovery from a major surgical procedure ≤ 14 days prior to randomization. - Psychiatric illness or social situations that would preclude study compliance. - Subject has another malignancy for which treatment is required. - Subject has any concurrent disease, infection or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
zolbetuximab +nab-paclitaxel + gemcitabine
Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
  • Drug: zolbetuximab
    Administered as an intravenous infusion.
    Other names:
    • IMAB362
  • Drug: nab-paclitaxel
    Administered as an intravenous infusion
  • Drug: gemcitabine
    Administered as an intravenous infusion
Active Comparator
nab-paclitaxel + gemcitabine
Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
  • Drug: zolbetuximab
    Administered as an intravenous infusion.
    Other names:
    • IMAB362
  • Drug: nab-paclitaxel
    Administered as an intravenous infusion
  • Drug: gemcitabine
    Administered as an intravenous infusion

Recruiting Locations

University of Kansas Cancer Center
Overland Park, Kansas 66210

More Details

Status
Recruiting
Sponsor
Astellas Pharma Global Development, Inc.

Study Contact

Astellas Pharma Global Development
800-888-7704
astellas.registration@astellas.com

Detailed Description

This study will have a safety lead in phase and a randomization phase.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.